Clinical Trial

Allo HSCT Using RIC and PTCy for Hematological Diseases

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-03-27; most recent amendment 2026-07-02.
Status change: Not Yet Recruiting → Recruiting 2023-05-02
Trial Details
NCT Number NCT05805605
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes +10 more
Enrollment 56 participants
Start Date 2023-05-01
Primary Completion 2027-10-22 (estimated)
Study Completion 2028-10-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-06